Clarivate, a company that sells data and analytics to researchers, universities and law firms, is shedding a business to slim down and pay off debt. It has agreed to sell its Life Sciences & Healthcare segment to the healthcare-focused investment firm Altaris for about $600 million, Clarivate said. Investors welcomed the move: the shares rose sharply, by about 16% in the wake of the announcement, according to Seeking Alpha.
The terms
The $600 million is not all cash on day one. Clarivate will receive $500 million in cash at closing, another $25 million once transition arrangements are complete, and a $75 million "seller note", effectively an IOU from the buyer, the company said. The sale is expected to close by the end of 2026, and Clarivate plans to use the money to reduce its debt and strengthen its balance sheet.
What Clarivate is keeping
Clarivate is best known for research and intellectual-property tools such as Web of Science, a database academics use to track published research, and patent-analytics products used by companies and law firms. After the sale, it will concentrate on two remaining segments, Academia & Government and Intellectual Property, which it says share overlapping customers and technology, per the company.
Chief executive Matti Shem Tov framed the deal as part of a "Value Creation Plan to optimize our business model, improve our sales execution, accelerate innovation and rationalize our portfolio," in the company's statement. In plainer terms: sell the piece that fits least well, cut debt, and focus on the parts that do.
The accounting, and the guidance
Divestitures often come with a paper loss, and this one is no exception: Clarivate expects to book a non-cash goodwill impairment of roughly $225 million to $250 million on the sale, the company said. A goodwill impairment is an accounting write-down of value the company had previously assigned to the business; it does not cost cash. Clarivate kept its 2026 forecast intact, guiding to revenue of $2.30 billion to $2.42 billion and adjusted core earnings (EBITDA) of $980 million to $1.04 billion, according to StockTitan.
Why the market liked it
The share-price jump reflects a common preference among investors for focus and a healthier balance sheet over sprawl. Clarivate had been reviewing its portfolio for months, having flagged a potential sale of the life-sciences unit earlier in the year. Selling it removes a business that fit awkwardly, brings in cash to reduce borrowings, and leaves a simpler company built around its strongest data assets, the kind of tidy-up that markets often reward, even when, as here, it comes with an accounting write-down attached.
